Using nanobodies to increase the sensitivity and resolution of chromatin profiling through uliCUT&RUN
Project Number1R21CA261737-01
Contact PI/Project LeaderHAINER, SARAH JANE Other PIs
Awardee OrganizationUNIVERSITY OF PITTSBURGH AT PITTSBURGH
Description
Abstract Text
PROJECT SUMMARY/ABSTRACT
DNA-binding proteins play crucial roles in all DNA templated processes, such as transcription, splicing,
replication, and DNA repair. DNA binding proteins include transcription factors that bind preferentially to certain
DNA sequences, and histone proteins that form the core of nucleosomes. Importantly, genomic location of
factors or histone proteins cannot be predicted in cell types by DNA sequence alone. Therefore, protein profiling
technologies are used to identify cell specific characteristics of functional binding.
The importance of DNA-binding proteins has motivated the continued development of experimental and
analytical methods to better identify and characterize these interactions. Genome-wide profiling by ChIP-seq is
a widely-used technique that has assisted in the characterization of countless chromatin binding proteins.
However, this technique is limited in its ability to characterize factor occupancy in samples with small cell
numbers and by the availability of specific and robust antibodies. These limitations have necessitated the
development of complementary methods and extensions of ChIP-seq to provide a more complete of biological
processes in the cell. Very recently, we optimized CUT&RUN, a new localization method, to profile factor
occupancy in extremely low cell populations, down to single cells and individual mouse blastocyst embryos
(termed uliCUT&RUN). This technical advancement has opened the opportunity to profile factor occupancy in
rare cell populations, such as patient biopsies. Furthermore, it permits for testing cell heterogeneity that occurs
in cell populations. However, practical limitations of this technology still include antibody development and
efficiency.
Camelid single-chain VHH antibodies or Nanobodies (Nbs) are a compelling new class of antibodies
characterized by exceptionally high solubility and thermostability. We have recently developed a robust pipeline
for the discovery and characterization of high-quality antigen-specific Nb repertoires. This pipeline has been
extensively tested and optimized for a dozen of antigens with different structures and immune responses. With
this approach, a large cohort of high-quality conformational Nb binders can be identified.
Here we propose to couple our expertise on Nb development and uliCUT&RUN to develop nanobody
specific CUT&RUN for low cell populations and apply this technology to single cells and rare cell populations.
The development and application of Nb-based uliCUT&RUN will be of wide use to the community and we are
well poised to develop this technology given our optimization of CUT&RUN is the first time single cell transcription
factor profiling has been accomplished and our expertise in the new field of Nb development. Further, results
from applying this technology to samples will continue to further our understanding of normal cell biology, but
also provide crucial information that will benefit efforts to determine the causes and consequences of abnormal
cellular states that are associated with disease.
Public Health Relevance Statement
PROJECT NARRATIVE
We recently had two technological breakthroughs in both developing a robust technological pipeline to produce
large versatile repertoire of antigen-specific camelid VHH single-chain antibodies/nanobodies and optimizing a
chromatin-bound protein localization technique for single cells which previously had not been possible. These
breakthroughs enable us to conceive of combining nanobody application to chromatin protein localization
studies. Development of this advanced technology will enable higher resolution maps of DNA binding protein
localization on chromatin and permit better application to rare and low cell populations.
No Sub Projects information available for 1R21CA261737-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R21CA261737-01
Patents
No Patents information available for 1R21CA261737-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R21CA261737-01
Clinical Studies
No Clinical Studies information available for 1R21CA261737-01
News and More
Related News Releases
No news release information available for 1R21CA261737-01
History
No Historical information available for 1R21CA261737-01
Similar Projects
No Similar Projects information available for 1R21CA261737-01